Gaurav Kapoor, MD
Interventional Cardiology · Coal City, ILNPI 1245225192
Payments from drug & device makers
Across 148 payments — averaging $41.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Cook Incorporated$1K
- Edwards Lifesciences$778
- Boston Scientific$344
- Medtronic$282
- Novo Nordisk$270
- plus $2K from 30 others
What the payments were for
- Consulting fees$1,00016%
- Travel & lodging$1,38322%
- Food & beverage$3,80061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 7 | $1,458 |
| Cook Incorporated | 2 | $1,042 |
| Edwards Lifesciences | 7 | $778 |
| Boston Scientific | 11 | $344 |
| Medtronic(2 entities) | 19 | $282 |
| Novo Nordisk | 10 | $270 |
| Boehringer Ingelheim | 7 | $255 |
| Merck | 12 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $153 |
| Johnson & Johnson | 9 | $135 |
| Abbott | 6 | $134 |
| Lexicon Pharmaceuticals, Inc. | 5 | $110 |
| Novartis | 5 | $105 |
| Philips North America LLC | 2 | $80 |
| Inspire Medical Systems, Inc. | 1 | $74 |
| Biotronik Inc. | 3 | $71 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $67 |
| Cardiovascular Systems Inc. | 1 | $62 |
| AstraZeneca | 3 | $56 |
| Terumo Medical Corporation | 3 | $55 |
| Amgen | 3 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Penumbra, Inc. | 2 | $41 |
| Pfizer | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Avinger Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Cardinal Health 414 LLC | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $16 |
| Altathera Pharmaceuticals LLC | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,183 in reported general payments places this provider in the 40th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 524 | $611,804 |
| EntrestoSacubitril/Valsartan | 238 | $375,055 |
| Repatha SureclickEvolocumab | 237 | $175,449 |
| XareltoRivaroxaban | 148 | $162,473 |
| JardianceEmpagliflozin | 79 | $113,623 |
| FarxigaDapagliflozin Propanediol | 44 | $58,611 |
| Praluent PenAlirocumab | 91 | $53,194 |
| Atorvastatin Calcium | 1,013 | $11,002 |
| Ezetimibe | 284 | $9,206 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $8,157 |
| Metoprolol Succinate | 516 | $7,380 |
| Potassium Chloride | 253 | $6,132 |
| ClopidogrelClopidogrel Bisulfate | 462 | $5,512 |
| Losartan Potassium | 411 | $5,330 |
| Carvedilol | 551 | $4,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $39 | $611,804524 claims |
| NovartisEntresto | $105 | $375,055238 claims |
| Johnson & JohnsonXarelto | $135 | $162,473148 claims |
| Boehringer IngelheimJardiance | $255 | $113,62379 claims |
| AstraZenecaFarxiga | $56 | $58,61144 claims |
| Esperion Therapeutics, Inc.Nexlizet | $21 | $8,15715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Coal City
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Justin LevisayEvanston$837K
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Sunil AgarwalSpringfield$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.